Skip to main content
    R

    Recursion Pharmaceuticals Inc (RXRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.72
    -0.18 (-6.37%)

    Market Cap: $1.99B

    Last updated: Nov 17, 2026 at 4:44 PM ET

    Recursion Pharmaceuticals Inc (RXRX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Recursion Pharmaceuticals (RXRX) has a market cap of $1.99B and an enterprise value of $1.45B. It kept -697.13% of revenue as net income over the last 12 months. Its share count is up 21.48% from a year earlier.

    Total Valuation

    Enterprise value is 27.10% below the market cap, as cash exceeds debt.

    Market Cap$1.99B
    Enterprise Value$1.45B
    Latest price (Nov 17, 2026)$2.72

    Key Dates

    The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 23, 2027 (expected)
    Last Earnings DateNov 2, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.98% in the quarter ended Sep 30, 2026 and grew 38.62% a year over 2 years.

    Shares Outstanding543.00M
    Shares Change (YoY)+21.48%
    Shares Change (QoQ)+1.98%
    Share Count Growth (2Y CAGR)+38.62%

    Valuation Ratios

    Sales and book value multiples are 21.6x and 1.6x. Its year-end P/S ranged from 25.3x to 107.3x from 2021 to 2025.

    P/S Ratio21.6x
    Forward P/S49.1x
    P/B Ratio1.6x
    P/TBV Ratio3.1x

    Valuation history and multiples

    Price Statistics

    The stock is down 34.30% over 52 weeks and trades 27.47% below its 50-day average.

    Beta (1Y)2.94
    52-Week Change-34.30%
    1-Month Change-24.65%
    3-Month Change-22.29%
    6-Month Change-4.56%
    5-Year Change-78.96%
    Total Return (1Y)-34.30%
    Total Return (3Y CAGR)-27.20%
    Total Return (5Y CAGR)-32.39%
    Return vs SPY (1Y)-46.17%
    Max Drawdown (1Y)-45.16%
    Max Drawdown (3Y)-82.47%
    Sharpe Ratio (1Y)-0.57
    Correlation with SPY (1Y)0.54
    50-Day Average$3.75
    200-Day Average$3.46
    52-Week Range$2.77 to $5.24
    RSI (14 Days)33.3
    Average Volume (20 Days)21.35M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 5.01x current liabilities, and total debt is 0.01x shareholder equity.

    Current Ratio5.01x
    Quick Ratio5.01x
    Debt / Equity0.01x

    Returns and Efficiency

    Return on invested capital is -51.83% over the last 12 months, against a 5-year average of -47.27%.

    Return on Equity (ROE)-52.51%
    Return on Assets (ROA)-38.93%
    Return on Invested Capital (ROIC)-51.83%
    Return on Capital Employed (ROCE)-43.71%
    ROE (5Y Average)-51.25%
    ROA (5Y Average)-38.13%
    ROIC (5Y Average)-47.27%
    Asset Turnover0.05x
    Receivables Turnover2.82x

    Scores

    RXRX has an Altman Z-Score of -0.75, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score-0.75
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $68.23M over the last 12 months is up 56.18% from the 12 months before.

    Revenue$68.23M
    Revenue Growth (YoY)+56.18%
    Gross Profit$19.93M
    Operating Income-$494.98M
    Pretax Income-$480.23M
    Net Income-$475.67M
    EBITDA-$406.38M
    EBIT-$480.23M
    Reported EPS (TTM)-$0.90

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 74.25% of the $1.22B in total assets.

    Cash and Equivalents$549.85M
    Total Debt$11.90M
    Net Cash$537.95M
    Net Cash Per Share$0.99
    Working Capital$493.10M
    Shareholder Equity$905.81M
    Book Value Per Share$1.67
    Tangible Book Value$471.43M
    Tangible Book Per Share$0.87
    Total Assets$1.22B
    Total Liabilities$315.90M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.95M of capital spending, operating cash flow left -$312.48M of free cash flow.

    Operating Cash Flow-$310.53M
    Capital Expenditures$1.95M
    Free Cash Flow-$312.48M
    FCF Per Share-$0.52
    Depreciation and Amortization$73.85M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -725.44%.

    Gross Margin29.21%
    Operating Margin-725.44%
    Pretax Margin-703.82%
    Net Margin-697.13%
    EBITDA Margin-595.58%
    EBIT Margin-703.82%
    FCF Margin-457.97%
    Gross Margin (5Y Average)22.28%

    Growth

    Revenue grew 23.30% a year over 3 years.

    Revenue Growth (3Y CAGR)+23.30%
    Revenue Growth (5Y CAGR)+79.91%
    Book Value Per Share Growth (2Y CAGR)+3.93%
    Tangible Book Per Share Growth (2Y CAGR)-11.81%

    Revenue and profit by year

    Dividends and Yields

    RXRX does not pay a dividend. Its free cash flow yield is -21.16%.

    FCF Yield-21.16%
    Buyback Yield-14.87%
    Shareholder Yield-14.87%

    Peer Position

    Against 9 similar companies, RXRX has the 3rd highest P/S.

    P/S Ratio21.6x vs 5.2x median
    ROIC-51.83% vs -47.54% median
    Revenue Growth (Trailing 4 Quarters, YoY)+56.18% vs +49.45% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -23.05% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-23.05%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RXRX

    What is RXRX's market cap?

    Recursion Pharmaceuticals has a market cap of $1.99B. Its enterprise value, which adds debt and subtracts cash, is $1.45B.

    How many shares of RXRX are outstanding?

    Recursion Pharmaceuticals has 543.00M shares outstanding. The count is up 21.48% from a year earlier.

    Does RXRX pay a dividend?

    No. Recursion Pharmaceuticals does not pay a dividend.

    How much debt does RXRX have?

    Recursion Pharmaceuticals has $11.90M of total debt and $549.85M of cash and equivalents, a net cash position of $537.95M.